Key Developments: Pluristem Therapeutics Inc (PSTI.PH)

PSTI.PH on Philadelphia Stock Exchange

2.58USD
15 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$2.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37
52-wk High
$4.62
52-wk Low
$2.54

Search Stocks

Latest Key Developments (Source: Significant Developments)

Pluristem Therapeutics Inc gets Patent in Singapore for 3D Cell Expansion Technology
Monday, 1 Dec 2014 03:00am EST 

Pluristem Therapeutics Inc:Has been granted a patent in Singapore titled 'Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy.Patent No. 170761 relates to methods of expanding adherent stromal cells from human placental or adipose tissue using Pluristem's three-dimensional technology.  Full Article

Pluristem Therapeutics Inc grants patents in Australia and New Zealand
Wednesday, 12 Nov 2014 03:00am EST 

Pluristem Therapeutics Inc:Announces that it has been granted a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications.Says the patent, titled 'Adherent cells from placenta and use of same in disease treatment' has been issued in Australia, Patent No. 2010322808, and in New Zealand, Patent No. 600651.  Full Article

Pluristem Therapeutics files for secondary public offerings
Monday, 13 Oct 2014 08:00pm EDT 

Pluristem Therapeutics Inc:Offers amount of $200,000,000 to be listed on Nasdaq SmallCap Market.  Full Article

Pluristem Therapeutics Inc initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial
Tuesday, 8 Jul 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says initiation of South Korean sites in Phase II study assessing PLacental eXpanded (PLX) cells in treatment of intermittent claudication (IC).Patient screening is underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial.Says trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients.Says In May, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.  Full Article

Pluristem Therapeutics receives patent in russia for treatment of inflammatory bowel disease using placenta-derived cells
Thursday, 19 Jun 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says Russia's Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled, "Methods of Treating Inflammatory Colon Diseases".Patent covers methods for treating ulcerative colitis or Crohn's disease using placenta-derived cells.Patent has already been issued to Pluristem in South Africa and is currently pending in several other jurisdictions.  Full Article

Pluristem Therapeutics Inc receives patent in india for cell therapy production methods and compositions
Monday, 16 Jun 2014 03:00am EDT 

Pluristem Therapeutics Inc:It has been granted Patent No. 261087 from India's Office of the Controller General of Patents.Patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company's key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells.Says it also covers the composition of cells derived using this methodesigns & Trade Marks for a patent titled.  Full Article

Pluristem Therapeutics Inc updates on phase I/II clinical trial
Thursday, 29 May 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says it it has enhanced its activity in the orthopedic indications for its PLacental eXpanded (PLX) cell therapies.In Jan. Pluristem announced positive results from its phase I/II clinical trial for the treatment of injured gluteal muscle after total hip arthroplasty (THA).  Full Article

Pluristem Therapeutics Inc to be added to new TA Tech-Elite Stock Index in Israel
Wednesday, 7 May 2014 03:00am EDT 

Pluristem Therapeutics Inc:Its shares of common stock will be added to a newly created TA Tech-Elite index on the Tel Aviv Stock Exchange.Scheduled for launch on May 11.TA Tech-Elite index will comprise shares of Israel's leading technology and biomed companies.  Full Article

Pluristem Therapeutics Inc's manufacturing facility approved by European auditors for phase III trials
Monday, 28 Apr 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says its new manufacturing facility has received European Union's Qualified Person Declaration.With this declaration, Pluristem is approved to use cell therapies manufactured at facility located in Haifa, Israel, in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III.Qualified Person inspection was conducted in line with the European Union's Good Manufacturing Practice (GMP) legislation, directives and guidelines.Audit focused on design, construction and validation of Pluristem's new facility, equipment, utilities, and quality management systems. Pluristem's manufacturing and cell expansion operations were deemed compliant with EU GMP requirements.  Full Article

Pluristem Therapeutics Inc approves Pluristem's commercial scale cell manufacturing process
Thursday, 6 Mar 2014 03:00am EST 

Pluristem Therapeutics Inc:United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of PLacental eXpanded (PLX) cell products.Granted approval for to manufacture these products in new commercial-scale cell manufacturing facility.  Full Article

Search Stocks